Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hartmann

Showing results (331-340 of 472) with videos related to

Pageof 48
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancerO Rick, C Bokemeyer, J Beyer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2016
Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO)Thomas Schmitt, Regine Mayer-Steinacker, Frank Mayer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)G Folprecht, T Gruenberger, W Bechstein, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|January 27, 2026
Rethinking Bacterial Osteolysis: Translational Evidence From a Porcine Model and Fracture-Related InfectionsAnton A N Peterlin, Nicole L Henriksen, Julie M Birch, et al.
Der Pathologe|August 17, 2010
[Molecular pathology of sarcomas. Update on the research group "Molecular Diagnosis of Sarcomas"]A V Rüsseler, B Brors, T Fischer, et al.
The Lancet. Oncology|November 28, 2009
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialGunnar Folprecht, Thomas Gruenberger, Wolf O Bechstein, et al.
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
Physical Review Letters|September 26, 2012
Role of antisite disorder on preamorphization swelling in titanate pyrochloresY H Li, B P Uberuaga, C Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized TrialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2019
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomaJoerg T Hartmann, Hans-G Kopp, Viktor Gruenwald, et al.
Pageof 48

Showing results (331-340 of 472) with videos related to

Sort By:
Pageof 48
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancerO Rick, C Bokemeyer, J Beyer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2016
Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO)Thomas Schmitt, Regine Mayer-Steinacker, Frank Mayer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)G Folprecht, T Gruenberger, W Bechstein, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|January 27, 2026
Rethinking Bacterial Osteolysis: Translational Evidence From a Porcine Model and Fracture-Related InfectionsAnton A N Peterlin, Nicole L Henriksen, Julie M Birch, et al.
Der Pathologe|August 17, 2010
[Molecular pathology of sarcomas. Update on the research group "Molecular Diagnosis of Sarcomas"]A V Rüsseler, B Brors, T Fischer, et al.
The Lancet. Oncology|November 28, 2009
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialGunnar Folprecht, Thomas Gruenberger, Wolf O Bechstein, et al.
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
Physical Review Letters|September 26, 2012
Role of antisite disorder on preamorphization swelling in titanate pyrochloresY H Li, B P Uberuaga, C Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized TrialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2019
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomaJoerg T Hartmann, Hans-G Kopp, Viktor Gruenwald, et al.
Pageof 48